14. (Amended) A chemically stable compressed tablet free of lactose which comprises about 1% to about 50% by weight of racemic fluoxetine, an optically pure enantiomer or a pharmaceutically acceptable salt thereof, and about 99% to about 50% by weight of at least one pharmaceutically acceptable excipient, wherein said tablet does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST.

38. (Amended) A stable pharmaceutical unit dosage form which comprises an optically pure enantiomer of racemic fluoxetine, or a pharmaceutically acceptable salt thereof, and one of more pharmaceutically acceptable excipients wherein said dosage form is not a capsule or gel cap and said tablet does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST.

REMARKS

Claims 1-38 are pending in this application for the Examiner's review and consideration. Claims 13, 14 and 38 have been amended to more clearly recite that which Applicants consider to be the invention. In particular, claims 13, 14 and 38 have been amended to recite a tablet that does not dissolve in less than three minutes when subjected to the DISSOLUTION TEST. No new matter has been added as a result of these amendments, which are supported by the Specification as originally filed. *See, e.g.*, Specification at page 18, lines 18-25.

As set forth on page 2 of the Final Office Action, the Examiner has withdrawn the objection to the abstract of the disclosure and the rejections of claims 12, 33 and 34 under 35 U.S.C. §112, second paragraph in view of Applicants' amendment dated June 22, 1999. Further, Applicants acknowledge that the objection of claims 33 and 34 under 37 C.F.R. §1.75 have been withdrawn, although the Examiner did not clearly indicate this in the Final Office Action. Applicants respectfully request confirmation of the withdrawal of the objection to claims 33 and 34 under 37 C.F.R. §1.75.

The Rejection Under 35 U.S.C. §102(b) Should Be Withdrawn

Claims 13-14, 16-18, 21-25, 28-30 and 35-38 were rejected under 35 U.S.C. § 102(b) as being anticipated by European Patent Application EP 0 693 281 A2 to Mendizabal ("Mendizabal") for the reasons set forth on pages 3-5 of the Final Office Action.